Intellia reports positive Phase III lonvo-z

Intellia Therapeutics reported positive topline Phase 3 results on April 27 for lonvoguran ziclumeran, or lonvo-z, its in vivo CRISPR/Cas9 treatment for hereditary angioedema, a rare genetic swelling disorder. The Cambridge, Massachusetts, company said the global HAELO study met its primary endpoint and all key secondary endpoints, with favorable safety and tolerability findings. (ir.intelliatx.com) Intellia also said it had started a rolling biologics license application with the U.S. Food and Drug Administration and was preparing for a possible U.S. launch in the first half of 2027, if approved. (biospace.com) The result puts lonvo-z at the front of a closely watched effort to bring gene editing directly into the body rather than editing cells outside it and reinfusing them. (ir.intelliatx.com) John Leonard, Intellia’s president and chief executive, said the readout marked “the first Phase 3 data reported for an in vivo gene editing therapy.” STAT reported that, if approved, lonvo-z would be the second approved CRISPR-based medicine after Vertex Pharmaceuticals’ Casgevy, and the first in vivo treatment. ### How strong was the Phase 3 efficacy signal? Intellia said a one-time infusion of lonvo-z reduced hereditary angioedema attacks by 87% versus placebo during the six-month efficacy evaluation period from weeks 5 to 28. The company reported a mean monthly attack rate of 0.26 in the lonvo-z arm compared with 2.10 in the placebo arm, with p<0.0001. (ir.intelliatx.com) The same update said 62% of patients in the lonvo-z arm were both attack-free and therapy-free during that six-month period, compared with 11% of patients on placebo. Intellia said all key secondary endpoints were met with statistical significance. (ir.intelliatx.com) ### What kind of study was HAELO? ClinicalTrials.gov identifies HAELO as a Phase 3, multinational, randomized, double-blind, placebo-controlled study of NTLA-2002, the former name for lonvo-z, in hereditary angioedema. The registry lists an estimated enrollment of 60 participants, though Intellia later reported that 80 patients were enrolled. Intellia said 52 patients received lonvo-z and 28 received placebo. (biospace.com) The company said 49% of participants were enrolled in the United States and 71% were on long-term prophylactic therapy at study entry, with those patients required to stop those therapies in the weeks before dosing. ### What did Intellia say about safety? (biospace.com) Intellia said the most common treatment-emergent adverse events during the primary observation period, from infusion through week 28, were infusion-related reactions, headache and fatigue. The company said all treatment-emergent adverse events reported as of the February 10, 2026 data cutoff were mild or moderate, classified as Grade 1 or Grade 2. (clinicaltrials.gov) The company also said no serious adverse events were observed in the lonvo-z arm. Intellia’s April 27 release did not include a full dataset or a peer-reviewed publication, and outside observers were still waiting for more detailed disclosure after the topline announcement. (biotechreporter.news) ### How is lonvo-z supposed to work? Intellia said lonvo-z is designed as a one-time outpatient treatment that uses in vivo CRISPR gene editing to inactivate the KLKB1 gene. The company said that mechanism is intended to permanently lower kallikrein and bradykinin levels, which are linked to hereditary angioedema attacks. (biospace.com) Hereditary angioedema causes recurrent and potentially life-threatening swelling attacks affecting areas including the face, upper airway, abdomen and extremities, according to Intellia’s release. ### What comes next for regulators and investors to watch? (biospace.com) April 27 was also the date Intellia said it initiated a rolling BLA submission to the FDA for lonvo-z. The company reiterated on May 11 that it anticipated a U.S. launch in the first half of 2027, if approved, and said existing cash resources were expected to fund operations at least into 2028. ClinicalTrials.gov lists HAELO’s estimated study completion as September 2027. (ir.intelliatx.com) Intellia has not yet published the full Phase 3 dataset in the materials reviewed here, making future conference presentations, regulatory filings and any peer-reviewed publication the next detailed checkpoints for investors and clinicians. (clinicaltrials.gov)